These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 17301739

  • 1. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U.
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
    Yang RX, Ren HX, Zhuang L, Gao CL, Dong C, Luo CX, Wang XN, Feng EF, He JC.
    Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M, Schüller J, Colombo T, Zucchetti M, Riva A.
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [Abstract] [Full Text] [Related]

  • 7. Epirubicin as adjuvant therapy in breast cancer.
    Earl H, Iddawela M.
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P, Biswas N, Coleman M.
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [Abstract] [Full Text] [Related]

  • 14. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
    Warm M, Kates R, Mallmann P, Dick M, Nawroth F, Harbeck N, Paepke S, Thomas A.
    Anticancer Res; 2007 Aug; 27(2):1031-8. PubMed ID: 17465239
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
    Esposito M, Venturini M, Vannozzi MO, Tolino G, Lunardi G, Garrone O, Angiolini C, Viale M, Bergaglio M, Del Mastro L, Rosso R.
    J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
    [Abstract] [Full Text] [Related]

  • 20. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
    Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE.
    J Clin Oncol; 2009 Jun 20; 27(18):2938-45. PubMed ID: 19364964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.